Posted by Michael Wonder on 30 Mar 2018
Regeneron CEO 'optimistic' will strike deals to lower $14,000 per-year cholesterol drug
29 March 2018 - Regeneron Pharmaceuticals CEO Leonard Schleifer is hopeful he can bargain with pharmacy benefit managers to lower the cost of its more than $14,000-per-year cholesterol drug for patients.
Earlier this month, he said the company is willing to lower the price. However, he said he wants to force the payers to make access straightforward for the patients who need it.
When asked Wednesday if he is now striking any deals, Schleifer said, "We're working hard at that and I'm optimistic on how that's going to work out.
